Kornimate/medical-research-clean huggingface dataset:
preliminary evaluation of a point-of-care liver function test

Conditions: HIV; Tuberculosis; Drug-Induced Liver Injury

Summary: the proposed preliminary field evaluation will compare a point-of-care (poc) transaminase test with the standard of care test used in an hiv clinic at the hospital for tropical diseases in ho chi minh city, vietnam.

the dfa transaminase test provides rapid categorical measurement of alt in a whole blood specimen taken via finger-stick. the test is based on the platform technology of "paper microfluidics" (also known as "patterned paper"), in which hydrophobic barriers are patterned into a sheet of paper in order to create microfluidic, hydrophilic paths within the paper, through which flow can be directed towards specific detection zones. the test is designed for visual color-coded readout in three alt ranges ("bins") that correspond to the ranges of ast and alt (\ 5x uln) currently used for clinical management decisions per us tb and hiv treatment guidelines. the bin cutoffs are common to treatment guidelines used around the globe, including those used by the vietnam ministry of health. the colorimetric readout is designed to be read by eye using a visual "read guide" allowing the reader to make a semi-quantitative estimate or assign a categorical value into one of three bins. alternatively, if the device is scanned (e.g. desk-top scanner) or photographed (e.g. cell phone or standard digital camera, see (9)) and read with image-analysis software, it should be possible to generate a quantitative result. additionally, multiple control zones notify the user of insufficient sample volume, hemolysis, or damaged reagents. the overall goal of this study is to conduct a preliminary field evaluation of an investigational transaminase test in a population at risk for dili. the primary objectives are: 1. determine device accuracy by measuring the percent agreement of the categorical visual readout dfa transaminase test and the standard of care tests used in the htd hiv clinic. 2. determine inter-operator variability. 3. determine device failure rate as defined by invalid test results.

Eligibility criteria:
inclusion criteria: * adult (\>18 years old) patients receiving hiv treatment through the htd clinic * must be receiving routine scheduled alt monitoring on day of enrollment * willing to undergo finger-stick in addition to routine care * must be able to provide informed consent. exclusion criteria: * hiv-negative, or hiv-positive but not on treatment * not receiving transaminase monitoring for routine care * unable or unwilling to provide informed consent * less than 18 years old
capacitive-resistive electric transfer therapy for recovery from running fatigue

Conditions: Running; Fatigue

Summary: reducing fatigue and improving the recovery capabilities of runners has gained more interest over the last years. recently, capacitive-resistive electric transfer (tecar) therapy is commonly used by physical therapists to help athletes recover from muscle fatigue. however, empiric evidence supporting the benefits of tecar to recovery is lacking. this study investigated the effects of a tecar treatment performed shortly after an exhausting training session on both physiological and biomechanical parameters of running.

in this randomized controlled crossover trial all subjects will perform two test protocols separated by 2 weeks. each protocol will comprise one exhausting training session (20-min warm-up consisted of 15-min of continuous self-paced running followed by 5-min of fast-finish progression runs increasing speeds (from approximately 60% to 80% of maximal heart rate, participant controlled), 10 x 500 m sprints at 90% of maximal heart rate with a 2-min rest period between bouts and a recovery phase consisting of 10-min of slow jogging). twenty-four hours after this exhausting training, subjects will perform an incremental running test on a treadmill (pre-intervention test) where subjects will start at 10 km/h for 6 min after which speed will be increased by 2 km/h every 6 min until a 16 km/h trial is completed. one hour after this test, in one protocol subjects will receive tecar therapy (tecar treatment group); in the other group (control group) participants will rest passively in a sitting position for 30-min period. to evaluate the relevance of the changes induced by tecar therapy/passive recovery, subjects will repeat the treadmill test 48 hours after the first test in both groups (72 hours after the exhaustive training).

Eligibility criteria:
inclusion criteria: * recreationally active (current participation in races and a 10-km race time \<34.5-min) exclusion criteria: * suffered from any injury within the preceding 4 months.

Keywords: capacitive-resistive electric transfer therapy radiofrequency therapy recovery intervention fatigue running
hit in people with type 1 diabetes

Conditions: Type1diabetes

Summary: few people with type 1 diabetes achieve exercise guidelines and many programmes designed to increase physical activity have failed. high-intensity interval training (hit) has been shown to be a time-efficient alternative to traditional moderate-intensity continuous training (mict) in various groups without type 1 diabetes. a single bout of hit does not increase the risk of hypoglycaemia in people with type 1 diabetes. this study aimed to assess whether hit a safe, effective and time-efficient training strategy to improve cardio-metabolic health and reduce the risk of hypoglycaemia in people with type 1 diabetes.

this study aimed to investigate whether 1) six weeks of high-intensity interval training (hit) induces similar improvements in cardio-metabolic health markers as moderate-intensity continuous training (mict) in people with type 1 diabetes, and 2) whether hit abolishes acute reductions in plasma glucose observed following mict sessions. fourteen sedentary individuals with type 1 diabetes (n=7 per group) completed six weeks of hit or mict 3 times per week. pre- and post-training measurements were made of 24h interstitial glucose profiles (using continuous glucose monitors (cgms)) and cardio-metabolic health markers (v ̇o2peak, blood lipid profile and aortic pulse wave velocity; apwv). capillary blood glucose concentrations were assessed before and after exercise sessions throughout the training programme to investigate changes in blood glucose during exercise in the fed state.

Eligibility criteria:
inclusion criteria: * duration of type 1 diabetes \>6 months * basal bolus regimen * no significant history of hyper- or hypoglycaemia (determined from medical history) exclusion criteria: duration of type 1 diabetes \<6 months, * insulin pump therapy * significant history of hyper- or hypoglycaemia (determined from medical history) * obesity (bmi \>30 kg∙m-2) * pregnancy or planning pregnancy * uncontrolled hypertension (\>180/100 mmhg) * angina, autonomic neuropathy * taking any medication that affects heart rate * major surgery planned within 6 weeks of the study * severe nonproliferative * unstable proliferative retinopathy
etiology and treatment of neonatal seizure

Conditions: Seizures; Seizure Disorder; Seizure Newborn; Seizure Generalized

Summary: genetic diagnosis for neonates suffering from epilepsy has important implications for treatment, prognosis, and development of precision medicine strategies. investigator performed exome sequencing (es) or targeted sequencing on neonates with seizure onset within the first month of life. investigator subgrouped our patients based on the onset age of seizure into neonatal and before 1 year (1-12 months), to compare the clinical and genetic features and treatment strategies.

seizure is one of the most common neurological conditions in neonates, and has substantial impact on patients'quality of life and social integration. epileptic encephalopathy is characterized by refractory seizures, cognitive dysfunction, and poor prognosis. despite the recent progress in technology, molecular diagnosis of neonates suffering from possible epileptic seizures can be challenging, due to genetic and phenotypic heterogeneities. a large number of specific pathogenic variations have been related to various forms of epilepsies. next-generation sequencing (ngs) has significantly improved the molecular diagnosis for rare diseases. ngs focusing on genes known to be associated with human diseases is a practical approach as a first-tier assessment for patients with heterogeneous genetic background. in addition, currently medical therapy for seizure is not based on the etiology, but the clinical manifestations, and the main purpose is not to rescue the underlying diseases process, but just to reduce the likelihood of seizures occurrence. in this study, investigator performed ngs on neonates with seizure onset before 1 year of age, to detect and quantify genetic variants, and assess existing therapeutic effects. our findings will have important implications for the development of precision medicine strategies.

Eligibility criteria:
inclusion criteria: * severe seizures in neonates or generalized epilepsy or intractable epilepsy in infancy with generalized tonic-clonic seizures, * seizures onset before 1 year of age, * epileptic syndromes/epileptic-encephalopathies with unknown etiology. exclusion criteria: * patients were excluded if they had traumas, central nervous system infections, hypoxic-ischemic encephalopathy, vascular events, systemic infections, and diagnosed metabolic disorders, and pathogenic copy-number variants were identified using array-based comparative genomic hybridization (cgh).

Keywords: seizure
casting vs bracing for idiopathic early-onset scoliosis

Conditions: Scoliosis Idiopathic; Early-Onset Scoliosis Deformity of Spine

Summary: comparison of casting and bracing for the treatment of idiopathic early onset scoliosis

this study uses a multicenter, prospective hybrid research design, which will combine two methods of treatment assignment (randomized and parent preference) and an embedded internal pilot study for sample size re-estimation. patients will be treated either with serial casts or a full-time brace and followed until curve resolution, failure or palliation (neither resolution nor failure after 2 years of treatment). results of this study will provide clinicians and families with evidence to support informed treatment decisions.

Eligibility criteria:
will enroll both patients with scoliosis and 1 of their parents/guardians inclusion criteria: patient inclusion * diagnosis of idiopathic early-onset scoliosis * child standing independently but not older than 3 years of age * 20≤ cobb angle ≤70° (largest structural curvature) * rib-vertebral angle difference (rvad) greater than 20 degrees or rib phase ii * parental consent to participate parent inclusion * parent or guardian of the minor subject * consent to participate * able to complete surveys exclusion criteria: patient exclusion * previous operative or non-operative treatment for idiopathic early-onset scoliosis * not independently walking by 18 months of age or other signs/symptoms indicative of developmental delay

Keywords: cast brace spinal orthosis spinal orthotic
exhaled breath condensate ph in patients with cough caused by gastroesophageal reflux

Conditions: Cough; Gastroesophageal Reflux

Summary: cough is the most common complaint for which patients seek medical attention in the united states, accounting for approximately 1 billion dollars in health care expenses annually. gastroesophageal reflux disease (gerd) is the sole cause of chronic cough in up to 20-40% of all cases. the majority of these patients with gerd-induced cough have no classic "heartburn" symptoms, so this important cause of cough can thus be difficult to detect. our hypothesis is that changes in exhaled breath condensate (ebc) ph can be used as a sensitive and non-invasive marker to identify subjects with cough caused by acid reflux.

gastroesophageal reflux disease (gerd) is the sole cause of chronic cough in up to 20-40% of all cases, and majority of these patients with gerd-induced cough have no classic "heartburn" symptoms. this important cause of cough can thus be difficult to detect. non-invasive radiologic tests for gerd such as barium swallow is imperfectly sensitive in subjects with gerd-induced cough. the 24 hour ph probe, which continuously monitors esophageal ph and can correlate cough events with reflux events, is considered to be the gold standard test. however, this test is expensive, invasive, and not universally available. the goal of the current study is to compare simultaneous measurements of esophageal ph with exhaled breath condensate ph after cough episodes, in patients with symptomatic cough. the cause of cough will be determined by a standard protocol, which includes 24 hour ph probe studies, and assessment for asthma, upper airway causes and sinus disease, and medication effects. all subjects will undergo 24 hour ph monitoring. during this monitoring period, they press an event button on the ph recording device to indicate a cough episode. after six such events, they will immediately perform an ebc collection, and ebc ph will subsequently be analyzed. differences between ph changes in the group with cough cause by gerd will be compared to ph measurements in the group with cough but no gerd, to determine the sensitivity and specificity of ph changes for discriminating between the two groups, and optimal threshold values for ph changes in ebc.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * able to speak and read english * chronic cough exclusion criteria: * cigarette smoking within the past 6 months, or greater than 10 pack year history of prior smoking * any self-reported or clinically diagnosed form of active lung disease, including asthma and emphysema * symptoms of persistent rhinitis within the past three months * dysphagia * symptoms of acute viral upper respiratory tract infection or sinusitis within one month of entry into the study * pregnancy - based on self report * abnormal chest radiograph

Keywords: cough gastroesophageal reflux exhaled breath condensate
the association between temporomandibular disorders and sacroiliac joint dysfunction

Conditions: Temporomandibular Joint Disorders; Temporomandibular Disorder

Summary: the aim of this study is to evaluate the relationship between temporomandibular disorders (tmd) and sacroiliac joint disfunction (sijd) and to determine the immediate effect of single-session orofacial manual therapy on sijd. patients will be treated for 1 session. the evaluation was planned to be done twice, at the beginning and end of the session.

the aim of this study is to evaluate the relationship between tmd and sijd and to determine the immediate effect of single-session orofacial manual therapy on sijd. patients diagnosed with both tmd and sijd will be participants of the study. patients will be treated for 1 session. immediately after the treatment, participants will be asked to walk for 5 minutes, after which a second assessment will be done. the evaluation was planned to be done twice, at the beginning and end of the session. pressure pain threshold, joint range of motion, functionality, and sacroiliac joint disfunction will be evaluated by using digital algometer, ruler, "oswestry disability index (odi)" and specific tests respectively.

Eligibility criteria:
inclusion criteria: * volunteered to participate, * aged between 18-60 years old, * having the diagnosis of temporomandibular disorders (tmb) and sacroiliac joint disfunction (sijd), exclusion criteria: * having a malignant condition, trauma and surgery of the cranial and cervical region, * not being cooperative, * regular use of analgesic and anti-inflammatory drugs, * having dentofacial anomalies, * having active inflammatory arthritis, * having metabolic diseases (gout, osteoporosis, cushing's disease and hyper/hypo-parathyroidism), * having connective tissue, rheumatological (systemic lupus erythematosus and scleroderma) and hematological disorders (anemia and leukemia), * having a diagnosed psychiatric illness, * receiving tmd-related physical therapy less than 6 months ago

Keywords: temporomandibular joint disorders temporomandibular joint sacroiliac joint orofacial pain
a study to evaluate zilovertamab vedotin (mk-2140) for relapsed or refractory diffuse large b-cell lymphoma (dlbcl) (mk-2140-004)

Conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Summary: the purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per lugano response criteria as assessed by blinded independent central review (bicr). safety and tolerability will also be evaluated in this phase 2, single arm, interventional study.


Eligibility criteria:
inclusion criteria: * has relapsed or refractory (rr) dlbcl; has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (sct) or are auto-sct ineligible. must have received prior multiagent regimen that includes an alkylating agent. anthracycline, and anti-cd20 (cluster of differentiation 20) monoclonal antibody. * has histologically confirmed diagnosis of dlbcl. * has radiographically measurable dlbcl per the lugano response criteria. * should either be post- chimeric antigen receptor t cell therapy (car-t) failure or ineligible for car-t (for any reason). * life expectancy of at least 3 months. * has an eastern cooperative oncology group (ecog) performance status of 0 to 2 assessed within 7 days before time of enrollment. * has adequate organ function. exclusion criteria: * has received a diagnosis of primary mediastinal b-cell lymphoma (pmbcl). * has undergone solid organ transplant at any time. * has a history of any clinically significant cardiovascular conditions within 6 months of screening or serious cardiac arrhythmia requiring medication. * has known history of liver cirrhosis. * has pericardial effusion or clinically significant pleural effusion. * has ongoing grade \>1 peripheral neuropathy. * has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. * transformed dlbcl from indolent lymphoma. * in participants with prior allo-sct, acute graft versus host disease (gvhd) or ongoing evidence of chronic gvhd. * has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention. * has received prior radiotherapy within 28 days of start of study intervention. participants. must have recovered from all radiation-related toxicities. * has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent). * has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. * is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. * has known active central nervous system (cns) lymphoma involvement or active cns involvement by lymphoma. * has an active infection requiring systemic therapy. * has a known history of human immunodeficiency virus (hiv) infection. * has a known history of hepatitis b or known active hepatitis c virus (hcv).
bioavailability of variably aged mk-0974 tablets (mk-0974-038)(completed)

Conditions: Migraine

Summary: this study will evaluate the comparative bioavailability of three capsule formulations of mk-0974.


Eligibility criteria:
inclusion criteria: * subject is in good health * subject is a nonsmoker * subject is willing to comply with the study restrictions exclusion criteria: * subject has a history of stroke, chronic seizures, or major neurological disorder * subject has a history of cancer * subject is a nursing mother * subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study
natural history study of adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in china

Conditions: Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

Summary: this is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis. this observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of ldh, hemoglobin, pnh-related symptoms and pnh-related events over 6 months. the other part is cross-sectional study to detect the total c5 level in pumch at the latest follow-up visit in eligible pnh patients with high-risk hemolysis, to show the difference between eligible pnh patients and healthy people and to explore the related clinical factor influencing high-level total c5 using logistic regression model.


Eligibility criteria:
inclusion criteria: 1. meet the diagnostic criteria for paroxysmal nocturnal hemoglobinuria; 2. age ≥ 18 years old; 3. pnh clone size of granulocytes or monocytes (cd59 or flaer) ≥ 10%; 4. ldh≥1.5 uln; 5. accompanied by at least one pnh-related symptoms: fatigue, hemoglobinuria, abdominal pain, dyspnea, anemia symptoms, major adverse vascular events (including thrombosis), dysphagia, erectile dysfunction; 6. transfusion-dependent pnh patients; 7. there are at least 6 months consecutive data of diagnosis and treatment after the data collection time point; 8. patients agreed to participate in the study by signing informed consent or giving oral informed consent. exclusion criteria: 1. patients are under the treatment of the c1/c3/c5 complement inhibitors currently or in the past; 2. patients have received bone marrow transplantation; 3. platelet count \<30\*10 9/l or absolute neutrophil count \<0.5\*10 9/l; 4. patients have clinically significant heart, liver, or lung diseases, or have related medical history. 5. patients have comorbidities of rheumatoid disease, hiv infection, active hbv infection, hcv infection and other diseases that affect the body's immune function; 6. severe missing data in the records of diagnosis and treatment after the data collection time point; 7. other patients who are not suitable to participate in the study.
implementation research of new dengue vector control tools

Conditions: DENGUE

Summary: this project will provide new insights concerning how to reduce dengue transmission by means of cost-effective and sustainable implementation strategies of vector control methods. the research will assess key strategies which deliver new vector control tools with respect to their cost-effectiveness, acceptability and sustainability in contrasting environments.


Eligibility criteria:
inclusion criteria: * no patients, but communities were included, with as inclusion criteria: neighborhoods of lam chabang, thailand and valera and san rafael de carvajal, venezuela after obtaining community approval exclusion criteria: * neighborhoods without community approval

Keywords: implementation research aedes vector control